Is Mounjaro good for your heart? What the clinical evidence shows

What the SURMOUNT trials found about heart-related markers

The headline figure from SURMOUNT-1, published in the New England Journal of Medicine, is an average body-weight reduction of around 20–21% at the 15mg dose over 72 weeks in adults with obesity. That number matters for the heart because excess adipose tissue (particularly visceral fat around the organs) drives chronic low-grade inflammation, raises blood pressure and worsens cholesterol and triglyceride profiles. When clinical trials measured these secondary endpoints, participants taking tirzepatide showed reductions in systolic blood pressure, meaningful falls in triglycerides and improvements in HDL cholesterol. These are not small quality-of-life refinements; they are recognised risk factors for coronary artery disease and stroke.

Researchers also observed reductions in waist circumference, a proxy for the visceral fat that sits closest to the heart and liver. For people with type 2 diabetes, who carry a substantially elevated cardiovascular risk at baseline, improvements in HbA1c and fasting glucose compound the benefit. The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, confirmed tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks in adults with obesity, suggesting its cardiometabolic secondary benefits are at least as large.

It is worth being precise about what the trials measured and what they did not. SURMOUNT-1 was a weight-loss trial that captured cardiovascular risk factors as secondary outcomes. It was not a dedicated cardiovascular outcomes trial in the mould of EMPA-REG or LEADER. Dedicated outcomes data for tirzepatide in a broader cardiovascular population are still accumulating.

How tirzepatide's dual mechanism relates to heart risk

The GLP-1 pathway (shared with semaglutide) has a reasonably well-understood relationship with cardiovascular health. GLP-1 receptors are expressed in cardiac tissue and blood vessels, and GLP-1 receptor agonists have demonstrated anti-inflammatory and vasodilatory properties in preclinical and clinical studies. Tirzepatide also activates GIP receptors, the second pathway that distinguishes it from all other licensed weight-loss medicines. GIP receptor signalling has its own metabolic effects, including on adipose tissue metabolism and insulin sensitivity. Whether this dual action adds a cardiovascular benefit beyond that achieved through weight loss alone is an active area of research rather than established fact.

What is established is that the degree of weight loss tirzepatide produces at its higher doses is large enough that the cardiovascular risk factors improve substantially even if the mechanism is simply the weight loss itself. A 20% reduction in body weight in someone with a BMI of 38 brings them into a meaningfully lower risk band. NHS guidance on treating obesity notes the broad health benefits that sustained weight loss confers, including on blood pressure and cholesterol.

People sometimes ask about Mounjaro in the context of related conditions that carry their own cardiovascular overlap. Fatty liver disease (explored further on our liver health page) is closely linked to insulin resistance and metabolic syndrome, both of which raise cardiovascular risk independently.

What Mounjaro is not licensed for, and the semaglutide comparison worth knowing

Semaglutide at 2.4mg (Wegovy) holds a UK authorisation for reducing the risk of major cardiovascular events (heart attack and stroke) in eligible adults with obesity and established cardiovascular disease, based on the SELECT trial. Tirzepatide does not yet hold this specific cardiovascular indication in the UK. That distinction matters. If a clinician is weighing up treatment for someone primarily because of cardiovascular risk rather than weight management, the licensing landscape is different. For questions about how the two medicines compare more broadly, our dedicated page on Mounjaro and heart effects covers the mechanistic detail, and our full Mounjaro overview sets out what the licence covers.

It is also worth noting that tirzepatide carries a small, transient increase in resting heart rate in some patients, an effect seen across the GLP-1 class and typically modest in absolute terms. This is monitored in clinical practice. People with certain pre-existing cardiac arrhythmias should discuss this with their prescriber before starting. If you have questions about alcohol on treatment, which has its own cardiovascular dimension, the guidance on drinking and Mounjaro is worth reading.

A prescriber will look at your full picture (blood pressure, lipid results, cardiac history, medications) before recommending any treatment. Our clinical team reviews every consultation personally. Pricing context, for those weighing up private access, is on the Mounjaro price comparison page.

When to get medical help

Most people tolerate tirzepatide well. The side effects most commonly reported are gastrointestinal (nausea, loose stools, reflux) and they are generally most noticeable in the first few weeks of a new dose, then settle. However, certain symptoms need prompt medical attention. Severe or persistent stomach pain that spreads to the back, with or without vomiting, should be assessed urgently: the MHRA issued a Drug Safety Update in January 2026 reminding prescribers and patients that acute pancreatitis, though infrequent, is a known risk with GLP-1 medicines. Palpitations that are new, chest pain, significant breathlessness or a sudden change in exercise tolerance should all prompt a call to your GP or 111, not because Mounjaro commonly causes these, but because anyone on treatment for weight or metabolic conditions deserves a low threshold for cardiac review. You can also report any suspected side effects directly via the Yellow Card scheme.

If you are considering treatment and want a prescriber to look at your individual cardiovascular history properly, a free consultation with nume, sorry. A free consultation with our team takes only minutes to start. Our prescribers review every application the same day, Monday to Friday.